{
  "id": 16960885,
  "title": "Viking Therapeutics falls on third quarter loss miss",
  "url": "https://urgent.news/2026/10/28/viking-therapeutics-falls-on-third-quarter-loss-miss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-28T21:12:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/viking-therapeutics-falls-on-third-quarter-loss-miss-4980926"
  },
  "original_language": "en",
  "account": "Viking Therapeutics Inc (NASDAQ:VKTX) reported a third quarter loss of $1.55 per share, missing analyst expectations by $0.49, as the company increased spending on its obesity drug development programs. The biopharmaceutical company's net loss for the period was $183.2 million, up from $90.8 million a year ago. Shares dropped 2.4% in after-hours trading. The higher loss was due to increased research and development expenses, which rose to $166.8 million from $90.0 million, and higher general and administrative expenses, up to $20.3 million from $8.6 million. Viking continued to advance its obesity drug development, including the SUNRISE Phase 3 program for oral VK2735 and ongoing Phase 3 trials for subcutaneous VK2735, expected to complete in 2027. The company also announced positive results from its VK2735 maintenance dosing study, showing weight loss retention of 82% to 97% among subjects on less frequent dosing regimens. Viking ended the quarter with $960 million in cash, up from $706 million at year-end 2025, following public offerings that raised about $575 million.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}